NEJM editorial advocates aspirin therapy for patients with colorectal cancer risk.
This article was originally published in The Tan Sheet
Executive Summary
ASPIRIN USE RECOMMENDED FOR COLORECTAL CANCER AT-RISK POPULATION in an editorial in the Sept.7 issue of the New England Journal of Medicine by Aaron J. Marcus, MD, New York Veterans Affairs Medical Center and Cornell University Medical College. Marcus advised that "people at risk for colorectal cancer -- those with inflammatory bowel disease; breast, ovarian, or endometrial cancer; or a previous adenoma or large-bowel cancer -- should take a single aspirin tablet (325 mg) every other day, barring any contraindication to this medication."